Invo Bioscience (OTCMKTS:IVOB – Get Rating) and InVivo Therapeutics (NASDAQ:NVIV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
18.6% of InVivo Therapeutics shares are held by institutional investors. 20.6% of Invo Bioscience shares are held by company insiders. Comparatively, 0.1% of InVivo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Invo Bioscience has a beta of -0.81, indicating that its stock price is 181% less volatile than the S&P 500. Comparatively, InVivo Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Valuation & Earnings
This table compares Invo Bioscience and InVivo Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Invo Bioscience||$490,000.00||328.22||-$3.08 million||N/A||N/A|
|InVivo Therapeutics||N/A||N/A||-$9.90 million||($7.69)||-0.63|
Invo Bioscience has higher revenue and earnings than InVivo Therapeutics.
This is a breakdown of current recommendations and price targets for Invo Bioscience and InVivo Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Invo Bioscience and InVivo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Invo Bioscience Company Profile (Get Rating)
INVO Bioscience, Inc. provides solutions in assisted reproductive technologies to the reproductive health care community in the United States, Asia, South America, Central America, Europe, the Middle East, India and Africa. The company offers the INVOcell device that is used in infertility treatment for the incubation of eggs and sperm during fertilization, and early embryo development. It also offers INVOcell Retention Device, a single-use, modified diaphragm that includes holes to allow for natural drainage of vaginal fluids; and INVO Holding/Warming Blocks that acts as a tool for viewing and retrieving the embryos from the inner chamber. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors. INVO Bioscience, Inc. is based in Medford, Massachusetts.
InVivo Therapeutics Company Profile (Get Rating)
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Invo Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invo Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.